Chenofalk ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
96. Crohn disease
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-013348-35-NL (EUCTR) | 04/08/2009 | 03/07/2009 | (Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. - Bile acid-FXR-FGF19 functioning in Crohn's disease | (Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. - Bile acid-FXR-FGF19 functioning in Crohn's disease | Patients with quiescent Crohn’s colitis, defined as a Crohn’s Disease Activity Index <150 ; non-IBD patients will serve as disease controls. MedDRA version: 9.1;Level: LLT;Classification code 10011400;Term: Crohn's colitis MedDRA version: 9.1;Classification code 10011401;Term: Crohn's disease MedDRA version: 9.1;Classification code 10011402;Term: Crohn's disease (colon) | Trade Name: Chenofalk Product Name: Chenofalk Product Code: RVG 07151 INN or Proposed INN: CHENODEOXYCHOLIC ACID Other descriptive name: Chenodiol | University Medical Center Utrecht | NULL | Not Recruiting | Female: yes Male: yes | Netherlands |